|
Jul 24
|
Exploring Three High Growth Tech Stocks In Asia
|
|
Jul 24
|
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
|
|
Jul 16
|
3 Asian Growth Companies With High Insider Ownership And 58% Earnings Growth
|
|
Jul 16
|
Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%
|
|
Jul 16
|
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
|
|
Jul 13
|
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
|
|
Jul 10
|
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
|
|
Jul 10
|
Agile Occupational Medicine and Akeso Occupational Health Merge to Form Leading West Coast Occupational Health Platform
|
|
Jul 9
|
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
|
|
Jun 25
|
High Growth Tech Stocks in Asia for June 2025
|
|
Jun 16
|
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
|
|
May 19
|
Asian Growth Companies With High Insider Ownership
|
|
May 19
|
Global Value Stocks: 3 Companies That May Be Priced Below Their Intrinsic Estimates
|
|
Apr 12
|
The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck’s Bestseller
|
|
Feb 14
|
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
|
|
Feb 13
|
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
|
|
Oct 13
|
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
|
|
Jul 29
|
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
|
|
Jan 8
|
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
|
|
Jan 5
|
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
|